Comparative analysis of risk prediction scores including all types of cancer-associated thrombosis.

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2026-04-01 Epub Date: 2025-10-26 DOI:10.1007/s12094-025-04099-2

Irene González Caraballo, Bárbara Lobato Delgado, Magdalena Ruiz Zamorano, Mercedes Salgado, Vanessa Pachón, Joaquina Martínez Galán, Victoria Castellón, Itziar Gardeazabal, Ana Ferrer, Jaime Rubio Pérez, Ignacio García Escobar, Isaura Fernández, Teresa Quintanar, Carme Font, Javier Soto Alsar, Laura Ortega Morán, José Manuel Soria Fernández, Andrés J Muñoz Martín

{"title":"Comparative analysis of risk prediction scores including all types of cancer-associated thrombosis.","authors":"Irene González Caraballo, Bárbara Lobato Delgado, Magdalena Ruiz Zamorano, Mercedes Salgado, Vanessa Pachón, Joaquina Martínez Galán, Victoria Castellón, Itziar Gardeazabal, Ana Ferrer, Jaime Rubio Pérez, Ignacio García Escobar, Isaura Fernández, Teresa Quintanar, Carme Font, Javier Soto Alsar, Laura Ortega Morán, José Manuel Soria Fernández, Andrés J Muñoz Martín","doi":"10.1007/s12094-025-04099-2","DOIUrl":null,"url":null,"abstract":"Background: Classically, risk assessment models have focused on classic, clinically symptomatic thrombotic events, such as deep vein thrombosis (DVT) and pulmonary embolism (PE), not taking into account incidental thrombosis or non-conventional thrombotic events such as catheter-related thrombosis (CRT) or splenic vein thrombosis (SVT), although they contribute to morbidity and increase the consumption of health resources.Methods: The primary objective was to evaluate and compare the predictive performance of the Khorana, PROTECHT, CONKO, modified VIENA-CATS (excluding P-selectin values), and MICA-CATS scores in assessing all type of thrombotic events in cancer patients (p) in the second cohort of the observational, multicenter, prospective ONCOTHROMB12-01 study. Data from 391 patients undergoing ambulatory systemic therapy across 11 Spanish hospitals between 2018 and 2021 were analyzed.Results: 95 patients (24.3%) developed a thrombotic event. MICA-CATS score showed the best predictive capacity for all thrombotic events, as assessed by both the AUROC and the AUPRC, with an AUROC of 0.61 (95% CI 0.54-0.67) and an AUPRC of 0.38 (95% CI 0.30-0.46). For incidental thrombotic events, both the PROTECHT (0.62, 95% CI 0.55-0.68) and MICA-CATS (0.60, 95% CI 0.51-0.68) scores demonstrated utility.Conclusions: Our findings demonstrate that MICA-CATS score has the best predictive capacity for overall venous thromboembolism (VTE) in cancer patients.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"1444-1450"},"PeriodicalIF":2.5000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-04099-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Classically, risk assessment models have focused on classic, clinically symptomatic thrombotic events, such as deep vein thrombosis (DVT) and pulmonary embolism (PE), not taking into account incidental thrombosis or non-conventional thrombotic events such as catheter-related thrombosis (CRT) or splenic vein thrombosis (SVT), although they contribute to morbidity and increase the consumption of health resources.

Methods: The primary objective was to evaluate and compare the predictive performance of the Khorana, PROTECHT, CONKO, modified VIENA-CATS (excluding P-selectin values), and MICA-CATS scores in assessing all type of thrombotic events in cancer patients (p) in the second cohort of the observational, multicenter, prospective ONCOTHROMB12-01 study. Data from 391 patients undergoing ambulatory systemic therapy across 11 Spanish hospitals between 2018 and 2021 were analyzed.

Results: 95 patients (24.3%) developed a thrombotic event. MICA-CATS score showed the best predictive capacity for all thrombotic events, as assessed by both the AUROC and the AUPRC, with an AUROC of 0.61 (95% CI 0.54-0.67) and an AUPRC of 0.38 (95% CI 0.30-0.46). For incidental thrombotic events, both the PROTECHT (0.62, 95% CI 0.55-0.68) and MICA-CATS (0.60, 95% CI 0.51-0.68) scores demonstrated utility.

Conclusions: Our findings demonstrate that MICA-CATS score has the best predictive capacity for overall venous thromboembolism (VTE) in cancer patients.

查看原文本刊更多论文

包括所有类型癌症相关血栓形成的风险预测评分的比较分析。

背景：传统的风险评估模型侧重于经典的临床症状性血栓形成事件，如深静脉血栓形成（DVT）和肺栓塞（PE），而没有考虑偶发血栓形成或非传统血栓形成事件，如导管相关血栓形成（CRT）或脾静脉血栓形成（SVT），尽管它们有助于发病率和增加卫生资源的消耗。方法：在观察性、多中心、前瞻性ONCOTHROMB12-01研究的第二队列中，主要目的是评估和比较Khorana、PROTECHT、CONKO、改良的VIENA-CATS（不包括p -选择素值）和MICA-CATS评分在评估癌症患者所有类型血栓形成事件(p)方面的预测性能。研究人员分析了2018年至2021年期间西班牙11家医院391名接受门诊全身治疗的患者的数据。结果：95例（24.3%）患者发生血栓形成事件。通过AUROC和AUPRC评估，MICA-CATS评分对所有血栓形成事件的预测能力最好，AUROC为0.61 (95% CI 0.54-0.67)， AUPRC为0.38 （95% CI 0.30-0.46）。对于偶发血栓事件，PROTECHT （0.62, 95% CI 0.55-0.68）和MICA-CATS （0.60, 95% CI 0.51-0.68）评分均显示出实用性。结论：我们的研究结果表明，MICA-CATS评分对癌症患者的全静脉血栓栓塞（VTE）有最好的预测能力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.